AVNS

Avanos is a turnaround-in-progress, not a growth story. The headline FY2025 net loss of -$72.9M looks alarming until you decompose it: the MD&A discloses a $77.0M goodwill impairment on the Pain Management & Recovery unit (Q2 2025), layered on $32.4M of Transformation Process restructuring costs (up from $8.9M in 2024). Strip those largely non-cash and one-time items and the underlying business still threw off $74.7M of operating cash flow and roughly $43M of free cash after $31.6M capex. The balance sheet backs this up: $778M equity against just $296M total liabilities (0.38x), $90M long-term debt nearly covered by $89.8M cash. This is not a company in financial distress.

But the quality bar for an upgrade isn't met. Revenue at $701M grew only 1.9% and has effectively flatlined for four years ($684M in 2022 → $701M in 2025), while gross profit actually fell 7.2% — margin compression on a stagnant top line. More damning is the pattern: the filing reveals $336.5M (Q4 2024 medical devices unit) plus $100.2M (Q4 2024 asset group) plus $77.0M (2025) of impairments in roughly 18 months, which is the financial signature of a serial acquirer that overpaid — the $780M accumulated deficit is the cumulative scar. The risk factors candidly flag that acquisitions 'may not result in the expected benefits, savings or synergies,' yet management just closed the Nexus and Diros deals, asking investors to trust the capital-allocation engine that produced those write-downs.